By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Astrazeneca UK Ltd. et al. v. Watson Pharmaceuticals, Inc. et al.
2:10-cv-01969; filed November 11, 2010 in the District Court of Nevada
• Plaintiffs: Astrazeneca UK Ltd.; IPR Pharmaceuticals, Inc.; Shionogi Seiyaku Kabushiki Kaisha
• Defendants: Watson Pharmaceuticals, Inc.; Watson Pharma, Inc.; Watson Laboratories, Inc.
Infringement of U.S. Patent No. RE37,314 ("Pyrimidine Derivatives," issued August 7, 2001) following a Paragraph IV certification as part of Watson's filing of an NDA to manufacture a generic version of AstraZeneca's Crestor® (rosuvastatin calcium, used to treat high cholesterol). View the complaint here.
Bristol-Myers Squibb Co. v. Apotex, Inc. et al.
3:10-cv-05810; filed November 8, 2010 in the District Court of New Jersey
• Plaintiffs: Bristol-Myers Squibb Co.
• Defendants: Apotex, Inc.; Apotex Corp.
Infringement of U.S. Patent Nos. 6,596,746 ("Cyclic Protein Tyrosine Kinase Inhibitors," issued July 22, 2003), 7,125,875 (same title, issued October 24, 2006), 7,153,856 (same title, issued December 26, 2006), and 7,491,725 ("Process For Preparing 2-Aminothiazole-5-Aromatic Carboxamides As Kinase Inhibitors" duly and legally issued on February 17, 2009) following a Paragraph IV certification as part of Apotex's filing of an ANDA to manufacture a generic version of Bristol-Myers' Sprycel® (dasatinib, used to treat adults chronic myeloid leukemia). View the complaint here.
Sanofi-Aventis U.S. LLC et al. v. Aurolife Pharma LLC et al.
2:10-cv-05801; filed November 5, 2010 in the District Court of New Jersey
• Plaintiffs: Sanofi-Aventis U.S. LLC; Aventisub II INC.; Carderm Capital L.P.
• Defendants: Aurolife Pharma LLC; Aurobindo Pharma Ltd.
Infringement of U.S. Patent Nos. 7,135,571 ("Processes for Preparing Anhydrous and Hydrate Forms of Antihistaminic Piperidine Derivatives, Polymorphs and Pseudomorphs Thereof," issued November 14, 2006), 6,399,632 ("Method of Providing an Antihistaminic Effect in a Hepatically Impaired Patient," issued June 4, 2002), 6,187,791 (same title, issued February 13, 2001), and 6,037,353 (same title, issued March 14, 2000) following a Paragraph IV certification as part of defendants' filing of an ANDA to manufacture a generic version of Aventis' Allegra ® (fexofenadine hydrochloride, used to treat allergies). View the complaint here.
Monsanto Co. et al. v. Southfork Farms, LLC et al.
1:10-cv-01290; filed November 5, 2010 in the Western District of Tennessee
• Plaintiffs: Monsanto Co.; Monsanto Technology, LLC
• Defendants: Southfork Farms, LLC; Scott Roland; William L. Johnson
Infringement of U.S. Patent Nos. 5,352,605 ("Chimeric Genes for Transforming Plant Cells Using Viral Promoters," issued October 4, 1994) and RE39,247 ("Glyphosate-tolerant 5-enolpyruvylshikimate-3-phosphate Synthases," issued August 22, 2006) based on defendants' use of soybean and cotton seed produced from earlier planted Roundup Ready® soybean and cotton seed. View the complaint here.
Triax Pharmaceuticals LLC et al. v. Glenmark Generics Inc. USA et al.
1:10-cv-00946; filed November 4, 2010 in the District Court of Delaware
• Plaintiffs: Triax Pharmaceuticals LLC; Astellas Pharma Europe B.V.; Astellas Pharma International B.V.
• Defendants: Glenmark Generics Inc. USA; Glenmark Pharmaceuticals Ltd.
Infringement of U.S. Patent No. 5,635,497 ("Topical Application Compositions," issued June 3, 1997), licensed to Triax, following a Paragraph IV certification as part of Glenmark's filing of an ANDA to manufacture a generic version of Triax's Locoid Lipocream® (hydrocortisone butyrate, used to treat eczema). View the complaint here.
Astrazeneca LP et al. v. Sandoz Inc.
1:10-cv-05785; filed November 4, 2010 in the District Court of New Jersey
• Plaintiffs: Astrazeneca LP; Astrazeneca AB
• Defendant: Sandoz Inc.
Infringement of U.S. Patent Nos. 6,598,603 ("Method for Treating Respiratory Diseases," issued July 29, 2003) and 7,524,834 ("Sterile Powders, Formulations, and Methods for Producing the Same," issued April 28, 2009) following a Paragraph IV certification as part of Sandoz’s filing of an ANDA to manufacture a generic version of Astrazeneca's Pulmicort Respules® (budesonide inhalation suspension, used to treat asthma). View the complaint here.
Comments